Expression and significance of miRNA-126 in patients with coronary in-stent restenosis

doi:10.3877/cma.j.issn.2095-655X.2017.02.002

Abstract

Abstract:

Objective

To observe the differences of miR-126 expression in peripheral blood of patients with coronary in-stent restenosis (ISR) and evaluate its significance.

Methods

Twenty-six cases of patients with ISR in the Cardiology of Affiliated Hospital of Jining Medical University from June 2014 to December 2015 were collected as ISR group, 40 patients without ISR as non-ISR group.The clinical data and coronary stenting data were calculated.The differences of miR-126 expression levels which were detected by real-time PCR were compared by t test between the two groups.The ROC curve was used to analyze the predicted value of miR-126 on ISR after coronary stenting.Bioinformatics predicted the target genes of miR-126 and performed functional analysis and enrichment of these target genes.The main biological functions of miR-126 and its possible mechanism in ISR were discussed.

Results

Comparison between the ISR and non-ISR group in terms of coronary lesion characteristics and surgical characteristics: there were no significant differences in the diameter of the stent [(3.21±0.88)mm, (3.15±0.67)mm], the length of the stent [(20.83±4.92)mm, (21.02±4.75)mm] and the maximum pressure of the stent release [(14.17±9.1)atm, (13.97±6.26)atm] (t=0.97, -1.04, 0.87; P>0.05). The expression of miR-126 in ISR group (0.63±0.38) was lower than that in non-ISR (1.39±1.03), the difference was statistically significant (t=-5.46, P<0.01). AUC of baseline miR-126 on the coronary stent after 12-18 months of ISR was 0.791 (95% CI 0.671 ~ 0.912, P<0.01). The targets gene of miR-126 were predicted by the database, and the function of these target genes was enriched.Its main directions were vascular endothelial growth factor signaling pathway, extracellular matrix and cell proliferation regulation.

Conclusions

miR-126 is associated with an increased risk of ISR during postoperative follow-up, and it is a predictor of ISR in patients with coronary stent.The biological function of miR-126 is mainly focused on the direction of vascular endothelial growth factor signaling pathway, which may be a way to participate in the ISR process.

Key words: Coronary artery disease, In-stent restenosis, MicroRNAs, Computational biology

Guanghe Wei, Feng Song, Shaohui Zhang, Lixin Liu, Qiang Su, Jianjun Wang, Zhencai Gao, Shufang Zhang. Expression and significance of miRNA-126 in patients with coronary in-stent restenosis[J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(02): 80-85.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2017.02.002

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2017/V05/I02/80

Figures/Tables 8

References 15

[1]	Nazari-Jahantigh M,Egea V,Schober A, et al.MicroRNA-specific regulatory mechanisms in atherosclerosis[J]. J Mol Cell Cardiol, 2015, 89(Pt A): 35-41.
[2]	李玉媚,欧和生. miRNA对血管内皮细胞功能调节的研究进展[J]. 中国动脉硬化杂志, 2014, 22(10): 1072-1076.
[3]	李云,宋银宏,吕云波. miR-126与血管的研究进展[J]. 基础医学与临床, 2015, 35(2): 257-261.
[4]	Kang SJ,Mintz GS,Park DW, et al. Mechanisms of In-stent restenosis after drug-eluting stent implantation intravascular ultrasound analysis[J]. Circ Cardiovasc Interv, 2011, 4(1): 9-14.
[5]	Xu BY,Xiang MX,Wang JA.Endothelial progenitor cells and in-stent restenosis[J]. Curr Stem Cell Res Ther, 2015, 10(4): 364-371.
[6]	Ravindranath RR,Romaschin A,Thompson M. In vitro and in vivo cell-capture strategies using cardiac stent technology-a review[J]. Clin Biochem, 2016, 49(1-2): 186-191.
[7]	Gareri C,De Rosa S,Indolfi C. MicroRNAs for restenosis and thrombosis after vascular injury[J]. Circ Res, 2016, 118(7): 1170-1184.
[8]	刘立新,张韶辉,魏广和, 等. miRNA-23a在扩张型心肌病中表达的意义[J/CD]. 中华诊断学电子杂志, 2016, 4(3): 206-209.
[9]	Santulli G. microRNAs distinctively regulate vascular smooth muscle and endothelial cells：functional implications in angiogenesis, atherosclerosis, and in-stent restenosis[J]. Adv Exp Med Biol, 2015(887): 53-77.
[10]	Van Rooij E. The art of microRNA research[J]. Circ Res, 2011, 108(2): 219-234.
[11]	Feng X,Tan W,Cheng S, et al.Upregulation of microRNA-126 in hepatic stellate cells may affect pathogenesis of liver fibrosis through the NF-κB pathway[J]. DNA Cell Biol, 2015, 34(7): 470-480.
[12]	Welten SM,Goossens EA,Quax PH, et al.The multifactorial nature of microRNAs in vascular remodelling[J]. Cardiovasc Res, 2016, 110(1): 6-22.
[13]	Miki K,Endo K,Takahashi S, et al.Efficient detection and purification of cell populations using synthetic microRNA switches[J]. Cell Stem Cell, 2015, 16(6): 699-711.
[14]	Olivieri F,Bonafè M,Spazzafumo L, et al.Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells[J]. Aging (Albany NY), 2014, 6(9): 771-787.
[15]	Jansen F,Yang X,Hoelscher M, et al.Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles[J]. Circulation, 2013, 128(18): 2026- 2038.

基线变量		ISR组(n＝26)	non-ISR组(n＝40)	χ²值/t值	P值
年龄(岁，±s)		64.12±6.94	61.80±9.26	0.90	>0.05
男性(例，%)		18(73.08)	29(72.50)	1.75	>0.05
不稳定型心绞痛(例，%)		16(61.54)	28(70.00)	8.06	<0.01
非ST抬高型心肌梗死(例，%)		7(26.92)	7(17.50)	6.22	<0.01
ST抬高型心肌梗死(例，%)		3(11.54)	3(7.50)	1.68	<0.05
高血压病(例，%)		17(65.38)	27(67.50)	2.13	>0.05
糖尿病(例，%)		14(53.85)	22(55.00)	0.74	>0.05
高脂血症(例，%)		10(38.46)	15(37.50)	0.69	>0.05
体质量指数(kg/m²，±s)		27.7±6.10	28.1±4.50	－1.04	>0.05
冠脉病变位置(例，%)		?	?	?	?
?	单支病变	15(57.69)	22(55.00)	0.75	>0.05
?	2支病变	8(30.77)	13(32.50)	0.66	>0.05
?	3支病变	3(11.54)	5(12.50)	0.61	>0.05
支架直径(mm，±s)		3.21±0.88	3.15±0.67	0.97	>0.05
支架长度(mm，±s)		20.83±4.92	21.02±4.75	－1.04	>0.05
支架释放最大压力(atm，±s)		14.17±9.10	13.97±6.26	0.87	>0.05
后扩张(例，%)		4(15.38)	7(17.50)	1.80	>0.05
介入手术成功(例，%)		26(100.00)	40(100.00)	0	>0.05

基线变量		ISR组(n＝26)	non-ISR组(n＝40)	χ²值/t值	P值
年龄(岁，±s)		64.12±6.94	61.80±9.26	0.90	>0.05
男性(例，%)		18(73.08)	29(72.50)	1.75	>0.05
不稳定型心绞痛(例，%)		16(61.54)	28(70.00)	8.06	<0.01
非ST抬高型心肌梗死(例，%)		7(26.92)	7(17.50)	6.22	<0.01
ST抬高型心肌梗死(例，%)		3(11.54)	3(7.50)	1.68	<0.05
高血压病(例，%)		17(65.38)	27(67.50)	2.13	>0.05
糖尿病(例，%)		14(53.85)	22(55.00)	0.74	>0.05
高脂血症(例，%)		10(38.46)	15(37.50)	0.69	>0.05
体质量指数(kg/m²，±s)		27.7±6.10	28.1±4.50	－1.04	>0.05
冠脉病变位置(例，%)		?	?	?	?
?	单支病变	15(57.69)	22(55.00)	0.75	>0.05
?	2支病变	8(30.77)	13(32.50)	0.66	>0.05
?	3支病变	3(11.54)	5(12.50)	0.61	>0.05
支架直径(mm，±s)		3.21±0.88	3.15±0.67	0.97	>0.05
支架长度(mm，±s)		20.83±4.92	21.02±4.75	－1.04	>0.05
支架释放最大压力(atm，±s)		14.17±9.10	13.97±6.26	0.87	>0.05
后扩张(例，%)		4(15.38)	7(17.50)	1.80	>0.05
介入手术成功(例，%)		26(100.00)	40(100.00)	0	>0.05

靶基因	TargetScanRelease 6.2	DIANA	PicTar	microRNA.org	阳性预测软件个数
PTPN9	＋	＋	＋	＋	4
FBXO33	＋	＋	＋	－	3
IRS1	＋	＋	＋	－	3
KANK2	＋	＋	－	＋	3
PLK2	＋	＋	＋	－	3
SPRED1	＋	＋	＋	－	3
ADAM9	＋	－	－	＋	2
CAMSAP1	＋	＋	－	－	2
CRK	＋	＋	－	－	2
F8A3	－	＋	－	＋	2
PEX5	＋	－	－	＋	2
PIK3R2	－	＋	－	＋	2
PLXNB2	＋	＋	－	－	2
PMM1	－	＋	－	＋	2
RGS3	＋	－	－	＋	2
SLC7A5	＋	－	－	＋	2
TOM1	＋	－	－	＋	2
ZNF131	－	＋	－	＋	2
ZNF219	＋	＋	－	－	2

靶基因	TargetScanRelease 6.2	DIANA	PicTar	microRNA.org	阳性预测软件个数
PTPN9	＋	＋	＋	＋	4
FBXO33	＋	＋	＋	－	3
IRS1	＋	＋	＋	－	3
KANK2	＋	＋	－	＋	3
PLK2	＋	＋	＋	－	3
SPRED1	＋	＋	＋	－	3
ADAM9	＋	－	－	＋	2
CAMSAP1	＋	＋	－	－	2
CRK	＋	＋	－	－	2
F8A3	－	＋	－	＋	2
PEX5	＋	－	－	＋	2
PIK3R2	－	＋	－	＋	2
PLXNB2	＋	＋	－	－	2
PMM1	－	＋	－	＋	2
RGS3	＋	－	－	＋	2
SLC7A5	＋	－	－	＋	2
TOM1	＋	－	－	＋	2
ZNF131	－	＋	－	＋	2
ZNF219	＋	＋	－	－	2

Please choose a citation manager

Content to export